Journal of Multiple Sclerosis and Neuroimmunology

Preliminary Survey on the Standardization of Korean Medical Terminology for Neuroimmunological Diseases: Preferences for Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease Terminology: Hye Lim Lee, Soonwook Kwon, Jin Myoung Seok, Sooyoung Kim, Seong-il Oh, Policy Committee of Korean Society of Neuroimmunology; J Mult Scler Neuroimmunol. 2026;17(1):11-13. Published online June 30, 2026; DOI: https://doi.org/10.59578/jmsni.2026.17.1.11-13; Full text PubReader ePub PDF

Collaboration between Medical Association and Patient Organizations to Overcome Rare Neurological Disorders: Ki Hoon Kim, Young Nam Kwon, Jun-Soon Kim, Sooyoung Kim, Seung Woo Kim, Kee Hong Park, Jin-Sung Park, Jeong Bin Bong, Jin Myoung Seok, Hung Youl Seok, Hye Lim Lee, Eunbin Cho, Byeoung-Jun Jeon, Seong-il Oh, Public Relations Committee of Korean Society for Neuroimmunology; J Mult Scler Neuroimmunol. 2025;16(1):8-18. Published online June 30, 2025; DOI: https://doi.org/10.59578/jmsni.2025.16.1.8-18
Cited By 1; Full text PubReader ePub PDF

Neuromyelitis Optica Spectrum Disorder without Anti-AQP4 Antibody after Treatment of Latent Syphilis: Ju Heon Lee, Young Gi Lim, 김용수, Joo Yeon Ham, Hee-Jung Song, Ae Young Lee, Eun Hee Sohn; J Mult Scler Neuroimmunol. 2016;7(2):59-62. Published online September 1, 2016; PDF

6,048	Autoimmune Nodopathy: When to Suspect and How to Treat?
5,192	National Consensus Guidance for Management of Refractory Myasthenia Gravis
3,875	The Clinical Utility of the Ocrelizumab for the Patients with Multiple Sclerorsis
2,927	Monoclonal Antibody Treatment for Relapse Prevention in Neuromyelitis Optica Spectrum Disorder
2,833	Clinicoradiological Factors for Predicting and Monitoring the Progression of Multiple Sclerosis

Cited By 3	National Consensus Guidance for Management of Refractory Myasthenia Gravis
Cited By 1	Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease Presenting as a Diffuse Pachymeningitis
Cited By 1	Collaboration between Medical Association and Patient Organizations to Overcome Rare Neurological Disorders
Cited By 1	Ocrelizumab's Place in the Therapeutic Landscape at its 2019 Launch in France

Search